The combination of arsenic, interferon-alpha, and zidovudine restores an " immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Kchour, Ghada ^a   Rezaee, SA R ^b   Farid, Reza ^b   Ghantous, Akram ^c   Rafatpanah, Houshang ^b   Tarhini, Mahdi ^d   Kooshyar, Mohamad Mehdi ^e   El Hajj, Hiba ^f   Berry, Fadwa ^a   Mortada, Mohamad ^a   Nasser, Roudaina ^f   Shirdel, Abbas ^e   Dassouki, Zeina ^f   Ezzedine, Mohamad ^a   Rahimi, Hossein ^e   Ghavamzadeh, Ardeshir ^g   de Thé, Hugues ^h   Hermine, Olivier ⁱ   Mahmoudi, Mahmoud ^b   Bazarbachi, Ali ^f  

^a LEBANESE UNIVERSITY   (Lebanon)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^d Islamic University in Lebanon   (Lebanon)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Arsenic; ATL; Cytokines; HTLV I; Immune deficiency; Interferon; Zidovudine

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MALE; REGULATORY T LYMPHOCYTE; T CELL LEUKEMIA; TH1 CELL; TH2 CELL; VIRUS LOAD;

ADULT; AGED; ARSENICALS; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HTLV-I INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; OXIDES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 84884966978     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-91     Document Type: Article

References (53)

1. Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T, Kikuchi M, Ichimaru M, Yunoki K, Sato I, et al. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer 1982, 29:631-635. 10.1002/ijc.2910290606, 6980846.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:7415-7419. 10.1073/pnas.77.12.7415, 350514, 6261256.
3. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The H, El-Sabban ME, Hermine O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004, 5:664-672. 10.1016/S1470-2045(04)01608-0, 15522654.
4. Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood 2011, 118:1736-1745. 10.1182/blood-2011-03-345702, 21673346.
5. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W, O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009, 27:453-459. 2737379, 19064971.
6. Hermine O, Wattel E, Gessain A, Bazarbachi A. Adult T cell leukaemia: a review of established and new treatments. BioDrugs 1998, 10:447-462. 10.2165/00063030-199810060-00003, 18020614.
7. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(Suppl 1):S20-S25.
8. Bunn PA, Schechter GP, Jaffe E, Blayney D, Young RC, Matthews MJ, Blattner W, Broder S, Robert-Guroff M, Gallo RC. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983, 309:257-264. 10.1056/NEJM198308043090501, 6602943.
9. Takatsuki F, Yamaguchi K, Hattori T. Adult T-cell leukemia/lymphoma. Retrovirus biology and human disease 1990, 147-159. New York: Marcel Dekker, Gallo RC Wong-Staal F.
10. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 1990, 64:5682-5687. 248630, 1976827.
11. Araya N, Sato T, Yagishita N, Ando H, Utsunomiya A, Jacobson S, Yamano Y. Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease. Viruses 2011, 3:1532-1548. 10.3390/v3091532, 3187691, 21994794.
12. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061. 10.1126/science.1079490, 12522256.
13. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol 2008, 38:901-937. 10.1002/eji.200890012, 18395855.
14. Yamada Y. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood 1983, 61:192-199.
15. Kohno T, Yamada Y, Akamatsu N, Kamihira S, Imaizumi Y, Tomonaga M, Matsuyama T. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005, 96:527-533. 10.1111/j.1349-7006.2005.00080.x, 16108835.
16. Chen S, Ishii N, Ine S, Ikeda S, Fujimura T, Ndhlovu LC, Soroosh P, Tada K, Harigae H, Kameoka J, et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol 2006, 18:269-277.
17. Matsubara Y, Hori T, Morita R, Sakaguchi S, Uchiyama T. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia 2005, 19:482-483. 10.1038/sj.leu.2403628, 15674359.
18. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol 1991, 79:428-437. 10.1111/j.1365-2141.1991.tb08051.x, 1751370.
19. Bazarbachi A, Hermine O. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Virus Res 2001, 78:79-92. 10.1016/S0168-1702(01)00286-6, 11520582.
20. Tobinai K. Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park) 2009, 23:1250-1256.
21. Taguchi H, Kinoshita KI, Takatsuki K, Tomonaga M, Araki K, Arima N, Ikeda S, Uozumi K, Kohno H, Kawano F, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:182-186. 10.1097/00042560-199606010-00012, 8680890.
22. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001, 113:375-382. 10.1046/j.1365-2141.2001.02737.x, 11380402.
23. Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115:4337-4343. 10.1182/blood-2009-09-242347, 20348391.
24. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28:4177-4183. 10.1200/JCO.2010.28.0669, 20585095.
25. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de The H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93:278-283.
26. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000, 96:2849-2855.
27. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, Staudt L, de The H, Bazarbachi A. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003, 101:4576-4582. 10.1182/blood-2002-09-2986, 12560223.
28. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004, 5:130-134. 10.1038/sj.thj.6200374, 15048063.
29. El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med 2010, 207:2785-2792. 10.1084/jem.20101095, 3005222, 21135137.
30. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532. 10.1182/blood-2009-03-211821, 19411628.
31. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006, 118:3054-3061. 10.1002/ijc.21688, 16425276.
32. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC, O'Garra A. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004, 172:5986-5993.
33. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, Utsunomiya A, Harada M, Kikuchi M. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004, 126:81-84. 10.1111/j.1365-2141.2004.04999.x, 15198736.
34. Toulza F, Nosaka K, Takiguchi M, Pagliuca T, Mitsuya H, Tanaka Y, Taylor GP, Bangham CR. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer 2009, 125:2375-2382. 10.1002/ijc.24664, 19544530.
35. Roncador G, Garcia JF, Maestre L, Lucas E, Menarguez J, Ohshima K, Nakamura S, Banham AH, Piris MA. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005, 19:2247-2253. 10.1038/sj.leu.2403965, 16193085.
36. Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K, Hasegawa D, Izumi T, Fujita H, Aratani S, Yagishita N, et al. Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One 2009, 4:e6517. 10.1371/journal.pone.0006517, 2715877, 19654865.
37. Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, Grant CW, Maric DA, Jacobson S. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 2005, 115:1361-1368. 1087174, 15864353.
38. Oh U, Grant C, Griffith C, Fugo K, Takenouchi N, Jacobson S. Reduced Foxp3 protein expression is associated with inflammatory disease during human t lymphotropic virus type 1 Infection. J Infect Dis 2006, 193:1557-1566. 10.1086/503874, 16652285.
39. Michaelsson J, Barbosa HM, Jordan KA, Chapman JM, Brunialti MK, Neto WK, Nukui Y, Sabino EC, Chieia MA, Oliveira AS, et al. The frequency of CD127low expressing CD4+CD25high T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis. BMC Immunol 2008, 9:41. 10.1186/1471-2172-9-41, 2515103, 18664281.
40. Hayashi D, Kubota R, Takenouchi N, Tanaka Y, Hirano R, Takashima H, Osame M, Izumo S, Arimura K. Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. J Neuroimmunol 2008, 200:115-124. 10.1016/j.jneuroim.2008.06.005, 18639344.
41. Ramirez JM, Brembilla NC, Sorg O, Chicheportiche R, Matthes T, Dayer JM, Saurat JH, Roosnek E, Chizzolini C. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol 2010, 40:2450-2459. 10.1002/eji.201040461, 20706985.
42. Mori N, Gill PS, Mougdil T, Murakami S, Eto S, Prager D. Interleukin-10 gene expression in adult T-cell leukemia. Blood 1996, 88:1035-1045.
43. Rautert R, Schinkothe T, Franklin J, Weihrauch M, Boll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008, 49:2091-2098. 10.1080/10428190802441339, 19021051.
44. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095. 10.1084/jem.170.6.2081, 2189521, 2531194.
45. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993, 81:2964-2971.
46. Washiyama M, Nishigaki K, Ahmed N, Kinpara S, Ishii Y, Kanzawa N, Masuda T, Kannagi M. IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines. FEBS Lett 2007, 581:5207-5212. 10.1016/j.febslet.2007.10.008, 17950728.
47. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood 2004, 104:3305-3311. 10.1182/blood-2004-01-0266, 15292059.
48. Xu X, Heidenreich O, Kitajima I, McGuire K, Li Q, Su B, Nerenberg M. Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis. Oncogene 1996, 13:135-142.
49. Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007, 120:2052-2057. 10.1002/ijc.22536, 17278106.
50. Li-Weber M, Giaisi M, Chlichlia K, Khazaie K, Krammer PH. Human T cell leukemia virus type I Tax enhances IL-4 gene expression in T cells. Eur J Immunol 2001, 31:2623-2632. 10.1002/1521-4141(200109)31:9<2623::AID-IMMU2623>3.0.CO;2-4, 11536160.
51. Portis T, Harding JC, Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood 2001, 98(4):1200-1208. 10.1182/blood.V98.4.1200, 11493471.
52. Nasr R, El Hajj H, Kfoury Y, de Thé H, Hermine O, Bazarbachi A. Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?. Viruses 2011, 3(6):750-769. 3185778, 21994752.
53. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108(3):1021-1029. 10.1182/blood-2006-01-0067, 1895862, 16569765.